[Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa].
We evaluated the clinical usefulness of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa as compared with conventional chemotherapy. The cases were comprised of 9 gastric cancers, 6 colorectal cancers, 1 appendiceal carcinoma, and 1 malignant tumor of retroperitoneum, all of which were observed to have peritoneal dissemination during surgical operations. Medications infused were CDDP in 14 cases, MMC in 4 cases, and 5-FU in 1 case. The patients with P2 and P3 findings (group A) were compared with other cases treated with conventional chemotherapy (group B). The average survival periods were, for gastric cancer patients, 6 months in group A and 8.6 months in group B; for the colorectal cancer group, 10.5 months in group A and 13.6 months in group B. The 6-month and 1-year cumulative survival rates for the gastric cancer patients were 100% and 0%, respectively in group A; 52% and 17%, respectively in group B. For the colo-rectal cancer group, the 6-month, 1-year, and 2-year cumulative survival rates were 75%, 75%, and 0%, respectively, in group A; 79%, 45%, and 14% respectively, in group B. These results did not show significant differences between the two groups. On the other hand, the average outpatient clinic visiting rates in the gastric cancer patients in groups A and B showed a significant difference; 72.6% (group A) and 46.8% (group B). Also, the rates in the colo-rectal cancer patients showed a significant difference; 69.6% (group A) and 61.5% (group B). As a result, the extension of the period of stay at home and visiting of our outpatient clinic for treatment was obtained in the group A. Consequently, this intraperitoneal cancer chemotherapy using an implantable reservoir was extremely effective in patients with peritonitis carcinomatosa for outpatient treatment over the long term without loss of quality of life for each patient.
Tsuji
Y
Y
Dept. of Surgery, Nikko Memorial Hospital.
Nishimura
A
A
Katsuki
Y
Y
Yasuda
T
T
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001202:Ascitic Fluid / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000150:complications*; D005069:Evaluation Studies as Topic; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D015918:Infusion Pumps, Implantable / Q000592:standards; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D010538:Peritonitis / Q000188:drug therapy*; D011379:Prognosis; D013274:Stomach Neoplasms / Q000150:complications*; D005641:Tegafur / Q000008:administration & dosage
D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; C017367:carmofur; D002945:Cisplatin; D005472:Fluorouracil